In an advanced breakthrough in hematological cancer therapy, the Food and Drug Administration (FDA) has approved the following drugs for AML patients with specific mutations: multitargeted kinase inhibitor midostaurin (Stone et al., 2017), FLT3-ITD, FLT3-TKD, c-Kit activity inhibitor gilteritinib (Perl et al., 2019), IDH1 mutant enzymes inhibitor ivosidenib (DiNardo et al., 2018), and IDH2 mutant enzymes inhibitor enasidenib (Stein et al., 2017). This evidence concerns the gene FLT3 and hematopoietic and lymphoid cell neoplasm.